Orally administered recombinant Lactobacillus casei vector vaccine expressing β-toxoid of Clostridium perfringens that induced protective immunity responses
Autor: | Majid Ezatkhah, Mojtaba Alimolaei, Mehdi Golchin |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Lactobacillus casei Clostridium perfringens Administration Oral medicine.disease_cause Enteritis law.invention Microbiology Enterotoxemia Mice 03 medical and health sciences Immune system law medicine Animals Mice Inbred BALB C Vaccines Synthetic General Veterinary biology Toxoid food and beverages Toxoids Vector vaccine medicine.disease biology.organism_classification Virology Lacticaseibacillus casei 030104 developmental biology Bacterial Vaccines Recombinant DNA Female |
Zdroj: | Research in Veterinary Science. 115:332-339 |
ISSN: | 0034-5288 |
Popis: | Clostridium perfringens types B and C cause enteritis and enterotoxemia in animals. The conventional vaccine production systems need time-consuming detoxification and difficult quality control steps. In this study, a modified β-toxoid gene was synthesized, cloned into the pT1NX vector, and electroporated into Lactobacillus casei competent cells to yield L. casei-β recombinant strain. Surface expression of the recombinant β-toxoid was evaluated by ELISA and confirmed by immunofluorescence microscopy. Vaccinated BALB/c mice with L. casei-β induced potent humoral and cell-mediated immune responses that were protective against lethal challenges with 100 MLD/mL of the β-toxin. Safety and efficacy of the recombinant clone was evaluated and the presumptive toxicity of L. casei-β was studied by toxicity test and histopathological findings, which were the same as negative controls. Our results support the use of L. casei as a live oral vector vaccine, and that the recombinant L. casei-β is a potential candidate for being used in the control of enterotoxemia diseases caused by C. perfringens types B and C. |
Databáze: | OpenAIRE |
Externí odkaz: |